PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 3, 2020
app pub date -
Aug 31, 2018
filing date -
Aug 31, 2017
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
This disclosure relates to an enhanced molecular-targeted approach that targets treatment-induced or native hypoxia present within cancers, specifically, but not limited to the treatment of metastatic prostate cancer with androgen deprivation therapy, such as anti-androgens. The disclosure describes the utility of combined inhibition of IL-8 and VEGF signalling to effect a combined therapeutic response of malignant disease, which is magnified under conditions of hypoxia. Thus, provided is a pharmaceutical combination for use in the treatment of cancer, the pharmaceutical combination comprising: a vascular endothelial growth factor (VEGF) signalling inhibitor; and an interleukin-8 (IL-8) signalling inhibitor; wherein said use comprises administration of the pharmaceutical combination to a patient receiving an anti-cancer therapy.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully